Novartis Shares Fall After Trial Failure
Novartis shares dropped 10 percent after its experimental drug del-desiran failed a late-stage study for a muscle-wasting disorder. This marks the second pipeline setback for the drugmaker in a single week.
Xurve View
Insights:
Xurve View
NOVARTIS AG-REG shares fell 10% on Tuesday morning after an experimental muscle-wasting drug failed a late-stage trial. The decline wiped out gains and marked the second pipeline setback in a week for the Switzerland-based drugmaker. Investors had relied on the treatment to drive growth as older revenue streams face patent expiries.
